CM
TVTX icon

Castleark Management’s Travere Therapeutics TVTX Stock Holding History

Castleark Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-178,034
Closed -$3.61M – 417
2015
Q3 		$3.61M Sell
178,034
-65,616
-27% -$1.94M 0.12% 206
2015
Q2 		$8.08M Buy
+243,650
New +$6.67M 0.22% 132

Other funds holding TVTX

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Castleark Management's TVTX Position: Q4 2015 in Review

Castleark Management sold out of Travere Therapeutics (TVTX) in Q4 2015, closing a stake of 178,034 shares — an estimated $3.61M sold.

Castleark Management first reported a position in TVTX in Q2 2015 and held it in 2 quarters. The position peaked at $8.08M in Q2 2015. 116 funds tracked by Wall St. Rank hold TVTX as of Q4 2015.

  • Castleark Management reported no remaining Travere Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Castleark Management sold 178,034 Travere Therapeutics shares in Q4 2015, an estimated $3.61M.
  • Castleark Management first reported a position in Travere Therapeutics in Q2 2015 and held it in 2 quarters.
  • Castleark Management's Travere Therapeutics position peaked at $8.08M in Q2 2015.
  • 116 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2015.

Based on Castleark Management's 13F filing for Q4 2015, filed 17 Feb 2016.